首頁
Made Scientific

7月 2026Made Scientific的市場佔有率分析

Discover Made Scientific, a pioneering force in cell therapy innovation. Learn how we're shaping the future with cutting-edge solutions to accelerate research and commercialization.

行業: N/A

域名madescientific.com

成立年份2019

僱員51 - 200

年度營收--

Made Scientific

Made Scientific（包含公司地區）

madescientific.com

查看更多網站流量與參與度資訊

Made Scientific的熱門網域總造訪量

了解Made Scientific市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

madescientific.com3.2K

透過銷售情報查看更多內容

Made Scientific的熱門網域平均造訪時長

分析Made Scientific參與度指標。

過去 3 個月平均造訪時長

子公司細目

madescientific.com00:00:36

透過銷售情報查看更多內容

Made Scientific的熱門網域平均頁面瀏覽量

了解Made Scientific如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

madescientific.com1.96

透過銷售情報查看更多內容

Made Scientific按網域劃分的熱門競爭對手

看起來這裡的數據不足

無可顯示數據

使用的熱門技術Made Scientific

这些是Made Scientific顶级域名使用的行业网站技术

付款與貨幣 (3)

Visa

付費廣告 (2)

TikTok Pixel

市場行銷 (2)

Google Marketing Platform

行動裝置 (2)

Meta Viewport

更多技術

9

檢視所有

新聞與訊號來自Made Scientific

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Pluristyx, Inc. integrated with Made Scientific, Inc. on Jun 4th '26.By aligning Pluristyx's iPSC reprogramming, engineering, and differentiation technology platforms and expertise with Made Scientific's GMP banking and downstream manufacturing capabilities under a single coordinated workflow, the companies give developers one point of accountability, removing the handoff risk and timeline drag that typically accompany bespoke iPSC programs.

新聞Made Scientific, Inc. signed new client Columbia Business School on Jun 1st '26.Made Scientific selected as manufacturer for Columbia University's autologous and allogeneic NOVAKnee program - a first-in-class living biologic total knee replacement.

新聞Cytorastem partners with Made Scientific, Inc..Dr. Serena's appointment comes as Cytora, together with its U.S. partners Made Scientific, Inc. and ZEO ScientifiX, Inc., advances its investigational novel allogeneic hOMSC therapy CytoraStem(TM) toward availability to patients under Florida's Senate Bill 1768, a stem cell access law enabling physician-delivered investigational stem cell therapies under defined conditions.